Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said ...

s treatment for schizophrenia failed in a study designed ... The trial would have supported a broader approval for the drug.

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia ... of all marketed drugs, and Boehringer adds to a growing list of partners that ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the ... the Cobenfy brand name for the treatment ...

Find out how LB Pharmaceuticals’ LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on ...

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy. The trial didn’t meet statistical significance, with only a minor 2-point ...

The pharma announced last week that Camzyos was unable to improve disease burden in non-obstructive hypertrophic cardiomyopathy. Bristol Myers Squibb’s schizophrenia drug Cobenfy failed to ...

Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study. Continue Reading View Comments "Kalkine Media dolor sit amet, ...